Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 7/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6075910 | 0.84 | MTNR1A (0.50) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL6076711 | 0.79 | MTNR1A (0.45) | MTNR1AMTNR1BCYP1A2ALOX15MAPT | |
| SCHEMBL14591350 | 0.77 | MTNR1A (0.69) | MTNR1AMTNR1BCYP1A2CA1CA2 | |
| SCHEMBL14591355 | 0.75 | MTNR1A (0.71) | MTNR1AMTNR1BCYP1A2CA1CA2 | |
| SCHEMBL7847638 | 0.74 | CYP1A2 (0.46) | CYP1A2ALOX15MAPT | |
| SCHEMBL6081951 | 0.74 | MTNR1A (0.48) | MTNR1AMTNR1BCA1CA2CA12 | |
| SCHEMBL10277925 | 0.71 | MTNR1A (0.56) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL11496541 | 0.71 | MTNR1A (0.72) | MTNR1AMTNR1BCYP1A2CA1CA2 | |
| SCHEMBL23923734 | 0.69 | CA1 (0.45) | MTNR1AMTNR1BCYP1A2CA1CA2 | |
| SCHEMBL23923736 | 0.69 | CA1 (0.45) | MTNR1AMTNR1BCYP1A2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7126012-B2 | Substituted cyclic compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-24 | — | — | US | disclosed |
| US-7115752-B2 | Substituted cyclic compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-03 | — | — | US | disclosed |
| US-20050124682-A1 | Substituted cyclic compounds | LESIEUR DANIEL (FR) | 2005-06-09 | — | — | US | disclosed |
| US-6872851-B1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LES LABORATORIES SERVIER (FR) | 2005-03-29 | — | — | US | disclosed |
| US-20050059729-A1 | Substituted cyclic compounds | LESIEUR DANIEL (FR) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059729-A1 | Substituted cyclic compounds | CCNY, CCNT2, TECR | MTNR1A 465/4885MTNR1B 414/4885CYP1A2 245/4885 |
| US-20050124682-A1 | Substituted cyclic compounds | CCNY, CCNT2, TECR | MTNR1A 465/4885MTNR1B 414/4885CYP1A2 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.